SARS-CoV-2 Main Protease now available at EUCODIS

We are proud to announce the addition of the SARS-CoV-2 main protease (SARS-CoV-2 Mpro) to our product portfolio. The SARS-CoV-2 Mpro enzyme was collaboratively developed by experts of EUCODIS and Biosynth Carbosynth for research purposes in Covid-19 diagnostics, drug development and for in vitro research on viral replication.

SARS-CoV-2 Mpro is a key enzyme for the successful replication and transcription of SARS-CoV-2 by digesting replicase polyproteins at conserved cleavage sites resulting in the initiation of the viral replicase. The absence of human homologues identifies SARS-CoV-2 Mpro as an attractive target for new drugs and diagnostic approaches.

The activity of SARS-CoV-2 Mpro can be evaluated using fluorogenic substrates like i.e. 7-amino-4-carbamoylmethylcoumarin also available by our partner Biosynth Carbosynth.

SARS-Cov-2, the coronavirus responsible for the Covid-19 pandemic, causes severe health threats and economical losses worldwide. Therefore, it is of great importance to quickly develop new treatments and solutions to diminish the risks attributed to the disease.

Please contact us to find out more about our SARS-CoV-2 Mpro.  


About Biosynth Carbosynth

Biosynth Carbosynth® is the new global brand created by the merger of two key players in the fine chemicals market. The organisation has branches in Switzerland, the United Kingdom, Slovakia, the USA, China, Japan and India as well as a worldwide distribution network that reaches the entire diagnostics industry. Biosynth Carbosynth is an innovative developer of reagents and biological active complex organic chemicals and is a world-leading expert in the field of enzyme substrates, carbohydrates and nucleoside chemistry. In recent years, Biosynth Carbosynth has successfully introduced innovative chromogenic, fluorogenic and luminescence-based systems into the field.

Die inhaltliche Verantwortung für diesen Beitrag liegt ausschließlich beim Aussender. Beiträge können Vorhersagen enthalten, die auf Erwartungen an zukünftige Ereignisse beruhen, die zur Zeit der Erstellung des Beitrags in Aussicht standen. Bitte verlassen Sie sich nicht auf diese zukunftsgerichteten Aussagen.

Als Life Sciences Organisation mit Sitz in Wien möchten Sie, dass LISAvienna auf Ihre News und Events hinweist? Senden Sie uns einfach Ihre Beiträge an news(at)